Anticuerpos monoclonales inhibidores de la proproteína convertasa subtilisina/kexina tipo 9: nuevas evidencias

Abstract

Monoclonal antibodies that target proprotein convertase subtilisin/kexin type 9 (PCSK9) increase recycling of low-density lipoprotein receptors, and reduce plasma levels of these lipoproteins by 50-60%. Moreover, these agents also decrease lipoprotein(a) levels and increase high-density lipoprotein levels, as well as having other beneficial effects on lipid metabolism. clínically, these drugs decrease the incidence of cardiovascular events in patients with chronic atherosclerosis and in those who have recently experienced acute coronary syndrome. Furthermore, in these patients, the use of alirocumab has been associated with lower overall mortality. Patients with extensive atherosclerosis, diabetic patients and those with a low-density lipoprotein level >100 mg/dL achieve the greatest clínical benefits. In general, these drugs are safe and appear to offer an excellent additional tool for treating dyslipidemia. Today, the challenge is to promote the use of these agents in patients with cardiovascular disorders in order to improve their prognosis.